Array Biopharma Inc., of Boulder, Colo., submitted two new drug applications to the FDA to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily for the treatment of those with BRAF-mutant advanced, unresectable or metastatic melanoma.